TPH1 and systemic lupus erythematosus: Accordingly, BEL administration in patients with SLE has been reported to improve levels of cytokines, including type 1 IFN,52 which contributes to Tph differentiation,53 promoting B-cell activation and inducing autoantibody production in SLE.